CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc.
Sumitomo Mitsui Trust Group Inc. reduced its stake in CRISPR Therapeutics AG ($CRSP) by 5.3% in the first quarter of 2026, selling over 104,000 shares to hold 1.85 million shares valued at approximately $88.2 million. Despite this reduction and the company reporting a Q1 EPS of -$1.28 and low revenue, analyst sentiment remains cautiously positive with a "Moderate Buy" consensus rating and an average price target of $67.78. Institutional investors collectively own 69.20% of the company's stock.









